EFFECTS OF IPRIFLAVONE ON BONE REMODELING IN PRIMARY HYPERPARATHYROIDISM

被引：20

作者：

MAZZUOLI, G ^{[1
]}

ROMAGNOLI, E ^{[1
]}

CARNEVALE, V ^{[1
]}

SCARDA, A ^{[1
]}

SCARNECCHIA, L ^{[1
]}

PACITTI, MT ^{[1
]}

ROSSO, R ^{[1
]}

MINISOLA, S ^{[1
]}

机构：

[1] UNIV ROME LA SAPIENZA,IST CLIN MED 2,CATTEDRA MED INTERNA,I-00185 ROME,ITALY

来源：

BONE AND MINERAL | 1992年 / 19卷

关键词：

IPRIFLAVONE; BONE REMODELING; PRIMARY HYPERPARATHYROIDISM;

D O I：

10.1016/0169-6009(92)90863-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism. Nine patients, 6 females and 3 males (mean +/- SD age 56 +/- 12.5 years) were treated with 1200 mg/day of ipriflavone by oral administration divided in 3 daily doses. All patients were treated for 21 days; in 5 patients treatment was prolonged to 42 days. In all patients the main serum and urinary parameters of bone remodeling were evaluated. The results suggest that ipriflavone affects bone remodeling by inhibiting bone resorption without affecting bone formation. Ipriflavone is, therefore, indicated in the treatment of metabolic bone diseases characterized by a high bone turnover.

引用

页码：S27 / S33

页数：7

共 16 条

[1]

AGNUSDEI D, 1989, DRUG EXP CLIN RES, V15, P97

[2]

AGNUSDEI D, 1990, CLIN MALATTIE OSSO S, V1, P35

[3]

BENVENUTI S, 1991, J BONE MINER RES, V6, P987

[4] TARTRATE-RESISTANT ACID-PHOSPHATASE ACTIVITY IN RAT OSTEOBLASTS AND OSTEOCYTES [J].

BIANCO, P ;

BALLANTI, P ;

BONUCCI, E .

CALCIFIED TISSUE INTERNATIONAL, 1988, 43 (03) :167-171

[5] IPRIFLAVONE INHIBITS OSTEOCLAST DIFFERENTIATION IN PARATHYROID TRANSPLANTED PARIETAL BONE OF RATS [J].

BONUCCI, E ;

BALLANTI, P ;

MARTELLI, A ;

MERETO, E ;

BRAMBILLA, G ;

BIANCO, P ;

BUFALINO, L .

CALCIFIED TISSUE INTERNATIONAL, 1992, 50 (04) :314-319

[6] TRANSFORMING GROWTH FACTOR-BETA INHIBITS FORMATION OF OSTEOCLAST-LIKE CELLS IN LONG-TERM HUMAN MARROW CULTURES [J].

CHENU, C ;

PFEILSCHIFTER, J ;

MUNDY, GR ;

ROODMAN, GD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (15) :5683-5687

[7]

LAU KHW, 1987, CLIN CHEM, V33, P458

[8] CLINICAL-VALUE OF THE MEASUREMENT OF BONE REMODELING MARKERS IN PRIMARY HYPERPARATHYROIDISM [J].

MINISOLA, S ;

SCARNECCHIA, L ;

CARNEVALE, V ;

BIGI, F ;

ROMAGNOLI, E ;

PACITTI, MT ;

ROSSO, R ;

MAZZUOLI, GF .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1989, 12 (08) :537-542

[9]

ORIMO H, 1990, OSTEOPOROSIS 1990, P2156

[10] CLINICAL USEFULNESS OF SERUM TARTRATE-RESISTANT ACID-PHOSPHATASE-ACTIVITY DETERMINATION TO EVALUATE BONE TURNOVER [J].